title: Docetaxel: new preparation. No first-line use in metastatic breast cancer.
abstract: (1) For the treatment of metastatic breast cancer, the reference first-line cytotoxic chemotherapy is an anthracycline-based combination such as doxorubicin + cyclophosphamide. (2) The clinical file on docetaxel in this indication mainly comprises data from a comparative trial of doxorubicin + docetaxel versus doxorubicin + cyclophosphamide in 429 patients. (3) In this trial the doxorubicin + docetaxel combination failed to increase the duration or quality of survival relative to the doxorubicin + cyclophosphamide combination, whereas its adverse effect profile was somewhat poorer (notably with a risk of severe neutropenia). (4) Docetaxel currently has no place in this setting.
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D005602:France; D020249:Hormone Replacement Therapy; D006801:Humans; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004317:Doxorubicin; D003520:Cyclophosphamide; D017239:Paclitaxel